Hypersensitivity Pneumonitis Market Trends

  • Report ID: 5180
  • Published Date: Sep 11, 2025
  • Report Format: PDF, PPT

Hypersensitivity Pneumonitis Market Growth Drivers and Challenges:

Growth Drivers

  • Rising Environmental Pollution – It is expected that rise in the release of harmful gases and chemicals into the air is anticipated to drive the growth of hypersensitivity pneumonitis market. Moreover, hypersensitivity pneumonitis is a long illness that is caused by an allergic reaction to certain substances (allergens) inhaled through the air.
    According to estimates, more than 6 million people die from air pollution-related causes worldwide each year.

  • Growing Geriatric Population- Hypersensitivity pneumonitis (HP) is a complex interstitial lung disease (ILD) that is more common among those older than 65 years owing to weekend immune response, and the rising count of older people across the globe is estimated to drive market growth.
    Lately, the number of individuals over 65 in the globe is more than 8% of the population, and this percentage is anticipated to increase to over 15% of the global population by 2050.

Challenges

  • Lack of Awareness – Owing to the absence of sufficient resources in low economic areas people the knowledge about prescription drugs such as corticosteroids is poor. This may impact the market growth as without proper knowledge this medication can be misused.

  • Risk Associated with Underdiagnosis and Misdiagnosis of Hypersensitivity Pneumonitis

  • Side Effects Associated with Long-Term Treatment

Base Year

2025

Forecast Period

2026-2035

CAGR

5.4%

Base Year Market Size (2025)

USD 1.51 billion

Forecast Year Market Size (2035)

USD 2.55 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of hypersensitivity pneumonitis is assessed at USD 1.58 billion.

The global hypersensitivity pneumonitis market size surpassed USD 1.51 billion in 2025 and is projected to grow at a CAGR of more than 5.4%, reaching USD 2.55 billion revenue by 2035.

The North America hypersensitivity pneumonitis market will dominate more than 37% share by 2035, driven by increasing healthcare spending and improvements in diagnostic and treatment access.

Key players in the market include Pfizer Inc., Svizera Healthcare Pvt. Ltd., Sanofi S.A., Novo Nordisk A/S, Eli lilly and Company, Bayer AG, Sun Pharmaceutical Industries Ltd., Novartis AG, Abbott Laboratories Inc., Astra Zeneca Plc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos